Clinical evidence of semaglutide for metabolic dysfunction-associated steatotic liver disease (MASLD): An updated meta-analysis - PubMed
5 hours ago
- #meta-analysis
- #MASLD
- #semaglutide
- Semaglutide significantly improves resolution of metabolic dysfunction-associated steatohepatitis (MASH) without worsening fibrosis.
- Pooled data showed no statistically significant improvement in fibrosis improvement (≥1 stage) with semaglutide.
- Semaglutide reduces liver stiffness and increases relative liver fat reduction of ≥30%.
- Significant reductions in AST, ALT, and cholesterol levels were observed with semaglutide treatment.
- Semaglutide is associated with a higher risk of gastrointestinal-related adverse events but not serious adverse events compared to controls.
- Anti-fibrotic efficacy of semaglutide appears stage-dependent and time-dependent, with significant reversal mainly in non-cirrhotic stages.